The purpose of this program is to create awareness about the emergence of NRG1 fusions as a clinically actionable target, leading to new opportunities to increase patient referral due to a greater understanding of this ERBB[/HER]-targeted agents in NRG1 fusion-positive cancers. Researchers still do not fully understand many aspects of this targeting, raising the importance of foundational education to apprise clinicians of the latest mechanistic and preclinical data, so they become more comfortable to ask and detect and then refer.